Mark Wildgust/X
Apr 27, 2025, 12:47
Mark Wildgust: Forefront of Innovation – The Story of Developing Bispecific Antibodies
Mark Wildgust, The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Looking forward to sharing the story of how the Johnson and Johnson Innovative Medicine team working in partnership with the medical community, Saad Z. Usmani Marivi Mateos Byoung Chul Cho, has been at the forefront of innovation in developing bispecifics in oncology.
More posts featuring Johnson and Johnson Innovative Medicine.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 27, 2025, 12:45
Apr 27, 2025, 12:36
Apr 27, 2025, 12:29
Apr 27, 2025, 12:28
Apr 27, 2025, 12:20
Apr 27, 2025, 12:20
Apr 27, 2025, 12:09